Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Applied Genetic

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Upgrades

Benzinga · Oct 4, 2022

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022

Upgrades

Benzinga · Sep 29, 2022

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga · Jul 26, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · Jul 13, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · Mar 22, 2022

Organisations

Charter Communications

127 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

35 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United Kingdom

149,566 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.